Literature DB >> 12918031

Inhibitor of complement, Compstatin, prevents polymer-mediated Mac-1 up-regulation of human neutrophils independent of biomaterial type tested.

S Schmidt1, G Haase, E Csomor, R Lütticken, H Peltroche-Llacsahuanga.   

Abstract

The inflammatory reaction after cell contact with polymer materials is primarily mediated by activated neutrophils and may, in some cases, lead to exhaustion of neutrophil cell function. A direct consequence of this can be impairment of local or even systemic host defense mechanisms, which in turn can result in foreign body infections. Neutrophil activation, as indicated by the up-regulation of the Mac-1 adhesion receptor, is a reliable parameter for estimating the inflammatory risk due to implanted biomaterials. Because at blood contact, biomaterials immediately acquire a material-specific layer of blood proteins on their surface, including fibrinogen, complement, and immunoglobulin G, it is generally believed that after biomaterial contact, neutrophil activation primarily occurs by interaction with this protein layer. In this study, using our recently established polymer bead in vitro assay, we investigated whether complement inhibition alone can reduce biomaterial-mediated neutrophil activation, independent of the type of polymer and, hence, also its surface chemistry. Complement inhibition was achieved by using Compstatin, a recently developed complement inhibitor that binds to the complement component C3 preventing C3 convertase formation. We revealed significantly reduced (p < or = 0.025) Mac-1 receptor expression levels after 45 min of blood contact with the following polymers (without and with Compstatin): 1. polyurethane, 98.3%, 13.6%; 2. polymethylmetacrylate, 88.5%, 11.0%; and poly-D,L-lactide, 71.8%, 8.4%. Although these three polymer types acquire material-specific protein layers because of their different surface chemistry, complement inhibition by Compstatin alone proved to be sufficient to reduce neutrophil activation after surface contact, thus reducing the risk of biomaterial-mediated inflammatory reaction. Copyright 2003 Wiley Periodicals, Inc. J Biomed Mater Res 66A: 491-499, 2003

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12918031     DOI: 10.1002/jbm.a.10031

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  7 in total

1.  New compstatin variants through two de novo protein design frameworks.

Authors:  M L Bellows; H K Fung; M S Taylor; C A Floudas; A López de Victoria; D Morikis
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

Review 2.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine.

Authors:  You-Qiang Wu; Hongchang Qu; Georgia Sfyroera; Apostolia Tzekou; Brian K Kay; Bo Nilsson; Kristina Nilsson Ekdahl; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2011-02-21       Impact factor: 5.422

Review 4.  Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

Authors:  Robert A DeAngelis; Edimara S Reis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

5.  Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin.

Authors:  Paola Magotti; Daniel Ricklin; Hongchang Qu; You-Qiang Wu; Yiannis N Kaznessis; John D Lambris
Journal:  J Mol Recognit       Date:  2009 Nov-Dec       Impact factor: 2.137

Review 6.  Clinical review: new technologies for prevention of intravascular catheter-related infections.

Authors:  Stefania Cicalini; Fabrizio Palmieri; Nicola Petrosillo
Journal:  Crit Care       Date:  2003-09-29       Impact factor: 9.097

Review 7.  Role of the Complement System in the Response to Orthopedic Biomaterials.

Authors:  Yvonne Mödinger; Graciosa Q Teixeira; Cornelia Neidlinger-Wilke; Anita Ignatius
Journal:  Int J Mol Sci       Date:  2018-10-27       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.